Skip to search formSkip to main contentSkip to account menu

lenalidomide

Known as: 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione, 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-, IMid-1 
A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of… 
National Institutes of Health

Related topics

Related topics

16 relations
Angiogenesis InhibitionBortezomib/Dexamethasone/Lenalidomide RegimenFibroblast Growth Factor 2, humanNCIt Antineoplastic Agent Terminology

Broader (2)

Angiogenesis InhibitorsImmunologic Factors

Narrower (3)

CC-5013CDC-501Revlimid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune… 
Highly Cited
2013
Highly Cited
2013
Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
What is known and objective:  High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration… 
Highly Cited
2012
Highly Cited
2012
Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding
Review
2012
Review
2012
Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is inadequate. Autologous stem… 
Highly Cited
2011
Highly Cited
2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
BACKGROUND In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time… 
Highly Cited
2010
Highly Cited
2010
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
8032 Background: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or relapsed/refractory… 
Highly Cited
2010
Highly Cited
2010
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the… 
Highly Cited
2008
Highly Cited
2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being… 
Highly Cited
2007
Highly Cited
2007
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
Multiple myeloma (MM) patients have a propensity for thromboembolic events (TE), and treatment with thalidomide/dexamethasone or… 
Review
2005
Review
2005
Stem cell transplantation in multiple myeloma
Single autologous transplantation High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)